SCHEMBL3473670

SCHEMBL3473670

COCOc1ccc(CCl)cc1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
APP P05067 6/20 0.37
NQO1 P15559 1/20 0.37
MMP2 P08253 1/20 0.36
MMP3 P08254 1/20 0.36
MMP9 P14780 1/20 0.36
MMP14 P50281 1/20 0.36
MAOB P27338 1/20 0.36
TTR P02766 1/20 0.36
HPGD P15428 1/20 0.36
IDO1 P14902 1/20 0.35
ALDH1A1 P00352 3/20 0.35
KDM4E B2RXH2 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
FYN P06241 1/20 0.35
MAPT P10636 1/20 0.34
ALOX15 P16050 1/20 0.34
CMA1 P23946 1/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11474319 0.83 TAAR1 (0.39) APPMAOB
SCHEMBL3589633 0.83 NQO1 (0.50) APPNQO1MMP2MMP3MMP9
SCHEMBL25986811 0.82 LTA4H (0.50) APPNQO1ALDH1A1SMN1; SMN2LMNA
SCHEMBL2982877 0.81 ACACB (0.42) APPKDM4EMAPT
SCHEMBL9830128 0.81 NQO1 (0.46) NQO1HPGDALDH1A1KDM4ESMN1; SMN2
SCHEMBL14341660 0.80 APP (0.47) APPMAOBIDO1SMN1; SMN2
SCHEMBL2127451 0.80 SMN1; SMN2 (0.47) NQO1MAOBHPGDALDH1A1SMN1; SMN2
SCHEMBL11357207 0.78 MMP2 (0.40) APPNQO1MMP2MMP3MMP9
SCHEMBL7855924 0.78 APP (0.37) APPNQO1MMP2MMP3MMP9
SCHEMBL6160052 0.78 FYN (0.47) APPNQO1MMP2MMP3MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101506267-B Weather-resistant and heat-stable polymers with improved flow components SABIC INNOVATIVE PLASTICS IP 2014-08-27 CN disclosed
CN-101160340-B Transparent compositions, methods for the preparation thereof, and articles derived therefrom GEN ELECTRIC 2012-06-27 CN disclosed
US-7838602-B2 Weatherable, thermostable polymers having improved flow composition SABIC INNOVATIVE PLASTICS IP B.V. (NL) 2010-11-23 US disclosed
US-7605221-B2 Aromatic polycarbonateester block or random copolymer and polysiloxane blend primarily containing isophthalic and terephthalic acids, resorcinol and dimethylsilanediol monomers; films are radiation transparent; improved ductility at lower temperatures; aircraft components SABIC INNOVATIVE PLASTICS IP B.V. (NL) 2009-10-20 US disclosed
CN-101506267-A Weather-and heat-stable polymers with improved flow components SABIC INNOVATIVE PLASTICS IP (NL) 2009-08-12 CN disclosed
EP-2032624-A1 WEATHERABLE, THERMOSTABLE POLYMERS HAVING IMPROVED FLOW COMPOSITION Sabic Innovative Plastics IP B.V. (NL) 2009-03-11 EP disclosed
US-7432327-B2 Transparent polymeric compositions comprising polysiloxane-polycarbonate copolymer, articles made therefrom and methods of making same SABIC INNOVATIVE PLASTICS IP B.V. (NL) 2008-10-07 US disclosed
CN-101160340-A Transparent compositions, methods for the preparation thereof, and articles derived therefrom GEN ELECTRIC (US) 2008-04-09 CN disclosed
US-7321014-B2 Transparent compositions, methods for the preparation thereof, and articles derived therefrom GENERAL ELECTRIC COMPANY (US) 2008-01-22 US disclosed
WO-2008002757-A1 WEATHERABLE, THERMOSTABLE POLYMERS HAVING IMPROVED FLOW COMPOSITION SABIC INNOVATIVE PLASTICS IP B.V. (NL) 2008-01-03 WO disclosed
US-20060142527-A1 Transparent compositions, methods for the preparation thereof, and articles derived therefrom SHPP GLOBAL TECHNOLOGIES B.V. (NL) 2006-06-29 US disclosed
US-6924388-B2 Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-08-02 US disclosed
US-20050159577-A1 Weatherable, thermostable polymers having improved flow composition SABIC GLOBAL TECHNOLOGIES B.V. (NL) 2005-07-21 US disclosed
US-20040092594-A1 Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2004-05-13 US disclosed
US-6632963-B1 Are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, as well as for the treatment of GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2003-10-14 US disclosed
CN-1346828-A Dicyclic aromatic compound and use thereof in human or animal medicine and cosmetic process CT INTERNAT DE RES ES DERMATOL (FR) 2002-05-01 CN disclosed
CN-1241558-A Bicyclic aromatic compounds and their use in human or veterinary medicine and in cosmetic processes GALDERMA RESEARCH DEV S N C (FR) 2000-01-19 CN disclosed
EP-0199281-B1 PYRIDAZINONE DERIVATIVES, PREPARATION THEREOF, AND INSECTICIDAL, ACARICIDAL, NEMATICIDAL, FUNGICIDAL COMPOSITIONS NISSAN CHEMICAL INDUSTRIES LTD. (JP) 1991-07-10 EP disclosed
US-4837217-A Pyridazinone derivatives, preparation thereof, and insecticidal, acaricidal, nematicidal, fungicidal compositions NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 1989-06-06 US disclosed
EP-0199281-A2 Pyridazinone derivatives, preparation thereof, and insecticidal, acaricidal, nematicidal, fungicidal compositions NISSAN CHEMICAL INDUSTRIES LTD. (JP) 1986-10-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092594-A1 Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof AHR, TYR, MC1R APP 2281/4885NQO1 624/4885MMP2 1612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.